1. At a Glance – Welcome to the Hospital Where Growth is Faster Than Compliance
Picture this.
A hospital chain that went from ₹0 revenue in FY23 to ₹40 Cr in FY25, boasting a 51% ROCE, 744% sales growth, and IPO funding in hand…
…and yet somehow forgot to submit quarterly results on time and got fined.
Ladies and gentlemen, welcome to Gujarat Kidney & Super Speciality Ltd — where kidneys are treated on time, but compliance deadlines? Not so much.
This is a company sprinting like a startup on Red Bull — acquiring hospitals, expanding beds, buying robotics equipment — all while its P/E is chilling at 83x, which basically means the market thinks this is the next Apollo Hospitals… but with Vadodara vibes.
But wait.
- IPO funds getting reallocated already
- Multiple acquisitions within weeks
- Company secretary resigns
- Exchange penalties for non-compliance
You’re not just reading a healthcare story.
You’re watching a Netflix series titled “Growth vs Governance: Who Wins?”
So the real question is:
👉 Is this India’s next hospital chain disruptor…
👉 Or a small-cap trying to grow faster than its systems can handle?
Let’s investigate.
2. Introduction – From Kidney Specialist to Acquisition Addict
Gujarat Kidney & Super Speciality Ltd (GKSSL) is essentially a regional hospital chain operating in central Gujarat.
Started in 2019 — which means it’s younger than some Zomato delivery boys — the company has aggressively expanded into:
- Nephrology (kidney care)
- Cardiology
- Oncology
- Orthopaedics
- Neuro sciences
And now?
It’s not just treating patients.
It’s collecting hospitals like Pokémon.
Within just a few months (Jan–Mar 2026), the company approved:
- 100% acquisition of Parekhs Hospital (₹77 Cr)
- 100% acquisition of Ashwini Medical Centre (₹14 Cr)
- 49% in Harmony Medicare (₹10.78 Cr)
- 51% in Patel Hospital + Pharmacy (~₹12.5 Cr)
That’s not expansion.
That’s a shopping spree.
But here’s where it gets interesting…
👉 This is an asset-light strategy — instead of building hospitals, they acquire existing ones.
Sounds smart, right?
Yes… but also risky.
Because when you buy multiple hospitals quickly:
- Integration becomes messy
- Quality control becomes tricky
- Financial reporting gets complicated
And guess what happened?
👉 They missed filing quarterly results. Got fined.
Coincidence?
Or early warning sign?
3. Business Model – WTF Do They Even Do?
Let’s simplify.
GKSSL runs mid-sized multi-speciality hospitals focused on:
- Secondary care (routine surgeries)
- Tertiary care (complex treatments like kidney transplants)
Their core strength?
👉 Kidney care (nephrology + urology)
Because in India:
- Diabetes is rising
- Hypertension is rising
- Kidney failure is rising
Basically, bad lifestyle = great business for them.
Revenue Model
They earn money from:
- OPD (outpatient consultations)
- IPD (admitted patients)
- Surgeries (high-margin)
- ICU stays (very high margin)
- Insurance & government schemes
Breakup:
- 68.8% → Self-pay patients
- 21% → Insurance
- 9.7% → Government schemes
Translation?
👉 Mostly cash-paying
